| Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27 HS Hsu, JH Lin, WC Huang, TW Hsu, K Su, SH Chiou, YT Tsai, SC Hung Cancer 117 (7), 1516-1528, 2011 | 167 | 2011 |
| Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma A Rajan, CR Heery, A Thomas, AL Mammen, S Perry, G O’Sullivan Coyne, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 116 | 2019 |
| Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53 TF Ho, CJ Ma, CH Lu, YT Tsai, YH Wei, JS Chang, JK Lai, PJ Cheuh, ... Toxicology and Applied Pharmacology 225 (3), 318-328, 2007 | 70 | 2007 |
| MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer YA Tang, RK Lin, YT Tsai, HS Hsu, YC Yang, CY Chen, YC Wang Clinical cancer research 18 (16), 4325-4333, 2012 | 66 | 2012 |
| Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10 MH Wu, YT Tsai, KT Hua, KC Chang, ML Kuo, MT Lin The Journal of nutritional biochemistry 23 (11), 1434-1439, 2012 | 47 | 2012 |
| Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) M Bilusic, S McMahon, RA Madan, F Karzai, YT Tsai, RN Donahue, ... Journal for immunotherapy of cancer 9 (3), 2021 | 33 | 2021 |
| Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced … JM Collins, RN Donahue, YT Tsai, M Manu, C Palena, ME Gatti‐Mays, ... The oncologist 25 (7), 560-e1006, 2020 | 23 | 2020 |
| A randomized phase II trial of mFOLFOX6+ bevacizumab alone or with AdCEA vaccine+ avelumab immunotherapy for untreated metastatic colorectal cancer JM Redman, YT Tsai, BA Weinberg, RN Donahue, S Gandhy, ... The Oncologist 27 (3), 198-209, 2022 | 18 | 2022 |
| Deregulation of p53 and RB transcriptional control leads to overexpression of DNA methyltransferases in lung cancer YA Tang, YT Tsai, RK Lin, HS Hsu, CY Chen, YC Wang Journal of Cancer Research and Practice 1 (1), 14-27, 2014 | 16 | 2014 |
| BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation YT Tsai, G Lozanski, A Lehman, EJ Sass, E Hertlein, SB Salunke, ... Leukemia Research 39 (11), 1270-1277, 2015 | 11 | 2015 |
| Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa YT Tsai, J Strauss, NJ Toney, C Jochems, DJ Venzon, JL Gulley, ... Journal for ImmunoTherapy of Cancer 10 (4), 2022 | 10 | 2022 |
| Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic RN Donahue, JL Marté, M Goswami, NJ Toney, YT Tsai, JL Gulley, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 9 | 2021 |
| BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia YT Tsai, A Lakshmanan, AM Lehman, EJ Sass, M Tran, F McClanahan, ... Blood Advances 1 (24), 2147-2160, 2017 | 6* | 2017 |
| First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma J Strauss, JL Deville, M Sznol, A Ravaud, M Maruzzo, RK Pachynski, ... Journal for Immunotherapy of Cancer 11 (5), 2023 | 4 | 2023 |
| STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T … JL Gulley, A Bayliffe, R Donahue, YT Tsai, K Liu, M Katraggada, J Hsu, ... European Journal of Cancer 174, S5, 2022 | 3 | 2022 |
| Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs). M McAdams, S Swift, RN Donahue, C Celades, YT Tsai, M Bingham, ... Journal of Clinical Oncology 41 (16_suppl), e20647-e20647, 2023 | 2 | 2023 |
| SO-28 a randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic … J Redman, S Gandhy, M Gatti-Mays, HA Sater, Y Tsai, R Donahue, ... Annals of Oncology 31, S227, 2020 | 2 | 2020 |
| Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs) A Rajan, H Chen, C Zhao, S Swift, A Mammen, A Brofferio, E Padiernos, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 2 | 2019 |
| Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer A Rajan, HA Sater, O Rahma, R Agajanian, W Lassoued, JL Marté, ... Journal for Immunotherapy of Cancer 12 (3), 2024 | 1 | 2024 |
| AT cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity J Hsu, RN Donahue, M Katragadda, J Lowry, W Huang, K Srinivasan, ... Science Translational Medicine 15 (724), eadi0258, 2023 | 1 | 2023 |
